Literature DB >> 22847734

Modeling of red blood cell life-spans in hematologically normal populations.

Rocío Lledó-García1, Robert M Kalicki, Dominik E Uehlinger, Mats O Karlsson.   

Abstract

Despite the impact of red blood cell (RBC) Life-spans in some disease areas such as diabetes or anemia of chronic kidney disease, there is no consensus on how to quantitatively best describe the process. Several models have been proposed to explain the elimination process of RBCs: random destruction process, homogeneous life-span model, or a series of 4-transit compartment model. The aim of this work was to explore the different models that have been proposed in literature, and modifications to those. The impact of choosing the right model on future outcomes prediction--in the above mentioned areas--was also investigated. Both data from indirect (clinical data) and direct life-span measurement (biotin-labeled data) methods were analyzed using non-linear mixed effects models. Analysis showed that: (1) predictions from non-steady state data will depend on the RBC model chosen; (2) the transit compartment model, which considers variation in life-span in the RBC population, better describes RBC survival data than the random destruction or homogenous life-span models; and (3) the additional incorporation of random destruction patterns, although improving the description of the RBC survival data, does not appear to provide a marked improvement when describing clinical data.

Entities:  

Mesh:

Year:  2012        PMID: 22847734     DOI: 10.1007/s10928-012-9261-5

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  31 in total

1.  Population cell life span models for effects of drugs following indirect mechanisms of action.

Authors:  Juan J Perez-Ruixo; Hui C Kimko; Andrew T Chow; Vladimir Piotrovsky; Wojciech Krzyzanski; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-12       Impact factor: 2.745

2.  The effect of fetal hemoglobin on the survival characteristics of sickle cells.

Authors:  Robert S Franco; Zahida Yasin; Mary B Palascak; Peter Ciraolo; Clinton H Joiner; Donald L Rucknagel
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

3.  A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus.

Authors:  Willem de Winter; Joost DeJongh; Teun Post; Bart Ploeger; Richard Urquhart; Ian Moules; David Eckland; Meindert Danhof
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-03-22       Impact factor: 2.745

Review 4.  The measurement and importance of red cell survival.

Authors:  Robert S Franco
Journal:  Am J Hematol       Date:  2009-02       Impact factor: 10.047

5.  Senescent cell antigen, band 3, and band 3 mutations in cellular aging.

Authors:  M M Kay
Journal:  Biomed Biochim Acta       Date:  1990

6.  Survival equations for red blood cells with statistical distributions in life spans.

Authors:  J J de Lima
Journal:  Eur J Nucl Med       Date:  1987

7.  Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects.

Authors:  Wojciech Krzyzanski; William J Jusko; Mary C Wacholtz; Neil Minton; Wing K Cheung
Journal:  Eur J Pharm Sci       Date:  2005-11       Impact factor: 4.384

8.  Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers.

Authors:  Rohini Ramakrishnan; Wing K Cheung; Mary C Wacholtz; Neil Minton; William J Jusko
Journal:  J Clin Pharmacol       Date:  2004-09       Impact factor: 3.126

9.  RBCs labeled at two biotin densities permit simultaneous and repeated measurements of circulating RBC volume.

Authors:  Donald M Mock; Gary L Lankford; John A Widness; Leon F Burmeister; Daniel Kahn; Ronald G Strauss
Journal:  Transfusion       Date:  2004-03       Impact factor: 3.157

Review 10.  Erythropoietin: physiology and pharmacology update.

Authors:  James W Fisher
Journal:  Exp Biol Med (Maywood)       Date:  2003-01
View more
  13 in total

1.  A semi-mechanistic red blood cell survival model provides some insight into red blood cell destruction mechanisms.

Authors:  Julia Korell; Stephen B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-06-18       Impact factor: 2.745

2.  Age-structured population model of cell survival.

Authors:  Wojciech Krzyzanski; Pawel Wiczling; Asfiha Gebre
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-03-29       Impact factor: 2.745

3.  A semi-mechanistic model of the relationship between average glucose and HbA1c in healthy and diabetic subjects.

Authors:  Rocío Lledó-García; Norman A Mazer; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-01-10       Impact factor: 2.745

4.  Modeling of delays in PKPD: classical approaches and a tutorial for delay differential equations.

Authors:  Gilbert Koch; Wojciech Krzyzanski; Juan Jose Pérez-Ruixo; Johannes Schropp
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-08-21       Impact factor: 2.745

5.  Population pharmacokinetics and pharmacodynamics of IONIS-GCGRRx, an antisense oligonucleotide for type 2 diabetes mellitus: a red blood cell lifespan model.

Authors:  Kenneth T Luu; Erin S Morgan; Sanjay Bhanot; Richard Geary; Anne Smith; Claudette Bethune; Lynnetta Watts; Scott Henry; Yanfeng Wang
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-01-28       Impact factor: 2.745

6.  Use of an oral stable isotope label to confirm variation in red blood cell mean age that influences HbA1c interpretation.

Authors:  Paramjit K Khera; Eric P Smith; Christopher J Lindsell; Mary Colleen Rogge; Shannon Haggerty; David A Wagner; Mary B Palascak; Shilpa Mehta; Jacqueline M Hibbert; Clinton H Joiner; Robert S Franco; Robert M Cohen
Journal:  Am J Hematol       Date:  2015-01       Impact factor: 10.047

7.  Models for the red blood cell lifespan.

Authors:  Rajiv P Shrestha; Joseph Horowitz; Christopher V Hollot; Michael J Germain; John A Widness; Donald M Mock; Peter Veng-Pedersen; Yossi Chait
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-04-02       Impact factor: 2.745

8.  Glycated Hemoglobin, Plasma Glucose, and Erythrocyte Aging.

Authors:  Manuel Beltran Del Rio; Mukesh Tiwari; Leo I Amodu; Joaquin Cagliani; Horacio Luis Rodriguez Rilo
Journal:  J Diabetes Sci Technol       Date:  2016-11-01

9.  Longitudinal Modeling of the Relationship Between Mean Plasma Glucose and HbA1c Following Antidiabetic Treatments.

Authors:  J B Møller; R V Overgaard; M C Kjellsson; N R Kristensen; S Klim; S H Ingwersen; M O Karlsson
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-10-30

10.  Effects of IL-1β-Blocking Therapies in Type 2 Diabetes Mellitus: A Quantitative Systems Pharmacology Modeling Approach to Explore Underlying Mechanisms.

Authors:  R Palmér; E Nyman; M Penney; A Marley; G Cedersund; B Agoram
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.